PK OF MYCOPHENOLATE MOFETIL W/ VALGANCICLOVIR IN RENAL & HEART TRANSPL RECIPENT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是评估伐更昔洛韦(VGCV)对肾和心脏移植患者体内如何处理霉酚酸酯(MMF)的影响。VGCV和MMF是FDA批准给肾和心脏移植患者的药物：vGCV用于预防巨细胞病毒感染，MMF用于抑制自身免疫系统对移植器官的排斥。活性形式的MMF和vGCV通过肾脏被清除，但当两种药物一起服用时，没有数据表明vGCV如何影响MMF在体内的浓度。由于MMF和vGCV都会引起相似的副作用，临床医生在决定是否应该减少一种或两种地毯的剂量时，经常受到挑战。测量药物浓度的12小时血液研究将在两种情况下进行：第一次研究在MMF和vGCV治疗期间进行，第二次研究在vGCV停用后仅使用MMF进行。如果MMF和VGCV之间存在相互作用，这项研究的结果将有助于临床医生制定剂量指南。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to evaluate the effects of valganciclovir (VGCV) on how the body handles mycophenolate mofetil (MMF) in kidney and heart transplant patients. VGCV and MMF are FDA-approved drugs given to kidney and heart transplant patients: VGCV to prevent cytomegalovirus infection and MMF to suppress their immune system to their body does not reject the transplanted organ. Active forms of MMF and VGCV are cleared through the kidney, but there is no data on how VGCV effects MMF concentrations in the body when two drugs are given together. Because both MMF and VGCV cause similar side effects, clinicians are often challenged when making decisions regarding whether the dosage of one or both rugs should be reduced. The 12-hour blood studies to measure drug concentrations will be conducted on 2 occasions: 1st study during MMF and VGCV therapy and 2nd study with MMF alone after VGCV discontinuation. The results of this study will help clinicians develop dosing guidelines if there is an interaction between MMF and VGCV.'